Menu
Modern therapies are often ineffective in treating life-changing diseases due to the complex and individual nature of the microbiome.
Age, ethnicity, diet and gender all have an impact on the composition of bacteria present in an individual’s gut, immune system or tumour physiology, which in turn influence whether drug treatments will have a positive or negative outcome.
Despite these factors, current drug development approaches remain uniform.
This leads to failed trials, poor outcomes and limited options for diverse populations, creating a significant financial impact on drug development, healthcare systems and a very personal cost for the people receiving treatment.
At BioCorteX, we have the most extensive and varied knowledge graph of microbiome samples in existence, consisting of millions of samples. These include human, animal, soil and water microbiomes, carefully selected from over 165 geopolitical regions and representing diverse populations worldwide.
With the help of Carbon MirrorTM, our foundational biology emulator, we can test the mechanistic link between the varied microbiome and the different treatment responses, and use this information to develop positive changes in future treatments.
The actionable insights created from this unique emulation capability means that BioCorteX can create new, sophisticated therapeutics that consider the differences in individuals and human populations. Therapeutics that are no longer uniform, but tailored to benefit different communities of people suffering from life-changing diseases. With a range of therapeutic options available, individuals will be able to confidently choose a treatment that works for them, successfully.
Senior Clinician
Scientist
Senior Data
Scientist
Microbiome
Data
Scientist
Senior Data
Engineer
Platform
Engineer
Data
Engineer
Senior Cloud
Architect
Full Stack
Engineer
Clinician
Scientist
CTO &
Co-Founder
Executive
Assistant
Director of
Technology
CEO &
Co-Founder
CTO &
Co-Founder
Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen. iduscius electo etur, cus invene qui cuptatium as aut audipsamus di
CEO &
Co-Founder
Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest o mmolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et as mmolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et as
Chair
Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen.
Board member & Partner
at Sofinnova Partners
Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen.
Board Member & Partner
at Hoxton Ventures
Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen.
Registered Address: 167-169 Great Portland Street,
5th Floor, London, W1W 5PF